Biofire FilmArray Meningitis/Encephalitis panel for the aetiological diagnosis of central nervous system infections: A systematic review and diagnostic test accuracy meta-analysis.

BACKGROUND: The FilmArray Meningitis/Encephalitis(FA/ME) panel brings benefits in clinical practice, but its diagnostic test accuracy (DTA) remains unclear. We aimed to determine the DTA of FA/ME for the aetiological diagnostic in patients with suspected central nervous system(CNS) infection. METHODS: We performed a systematic review with DTA meta-analysis (PROSPERO: CRD42020139285). We searched Embase, Medline (Ovid), and Web of Science from inception until September 1st, 2021. We assessed the study-level risk of bias with the QUADAS-2 tool and applied the GRADE approach to assess the certainty of the synthesised evidence. We included studies that simultaneously measured the reference test (CSF/blood culture for bacteria, and specific polymerase chain reaction for viruses) and the FA/ME in patients with suspected CNS infection. We performed random-effects bivariate meta-analysis models of combined sensitivity and specificity using CSF/blood cultures(reference test 1) and a final diagnosis adjudication based on clinical/laboratory criteria (reference test 2). FINDINGS: We included 19 studies (11,351 participants). For all bacteria with reference test 1 (16 studies/6183 patients) sensitivity was estimated at 89·5% (95%CI 81·1-94·4), and specificity at 97·4% (95%CI 94-98·9). With reference test 2 (15 studies/5,524 patients), sensitivity was estimated at 92·1%(95%CI 86·8-95·3) and specificity at 99.2(95%CI 98·3-99·6) For herpes simplex virus-2(HSV-2), enteroviruses, and Varicella-Zoster virus (VZV), we obtained sensitivities between 75·5 and 93·8%, and specificities above 99% (reference test 1). Certainty of the evidence was low. INTERPRETATION: FA/ME may have acceptable-to-high sensitivities and high specificities for identifying bacteria, especially for S.pneumoniae, and viruses, especially for HSV-2, and enteroviruses. Sensitivities for L.monocytogenes, H.influenzae, E.coli, and HSV-1 were suboptimal. FUNDING: None.

Características clínicas y del electroencefalograma de amplitud integrada en recién nacidos con encefalopatía hipóxico-isquémica bajo protocolo de hipotermia corporal total / Clinical and integrated amplitude electroencephalogram characteristics of newborns with hypoxic-ischemic encephalopathy under the protocol of total body hypothermia

RESUMEN La encefalopatía hipóxico-isquémica (EHI) es causa importante de mortalidad y discapacidad neurológica en neonatos. La evidencia sugiere que la terapia de hipotermia es capaz de impactar estos desenlaces. Este estudio se realizó con el objetivo de describir las características clínicas y las ayudas diagnósticas realizadas a recién nacidos con EHI sometidos a terapia de hipotermia corporal total con el uso de criterios preestablecidos de ingreso a la terapia, en una muestra de dos instituciones de la ciudad de Medellín. MÉTODOS: Se realizó un estudio descriptivo en el periodo 2017-2018, incluyendo la totalidad de pacientes con EHI ingresados a terapia de hipotermia. RESULTADOS: Se obtuvieron datos de 256 pacientes, con predominio masculino (182; 71,1%). Se evidenciaron fallas en el registro y subjetividad en la aplicación de los criterios de ingreso al protocolo de hipotermia en ambas instituciones. En 197 pacientes (77 %) no hubo reporte de evento centinela, y el expulsivo prolongado fue considerado por los clínicos un hallazgo significativo a la hora de definir el ingreso a la terapia. Hubo, además, pacientes ingresados que no cumplieron con el criterio de APGAR ≤ 5 a los 10 minutos (n = 136). Los resultados sugieren la necesidad de mejorar la adherencia al protocolo de ingreso a la terapia, pero al mismo tiempo señalan la importancia del concepto del clínico a la hora de abordar cada paciente de manera individual.

SUMMARY Hypoxic-ischemic encephalopathy (HIE) is an important cause of mortality in the neonatal population and neurological disability. The evidence shows that hypothermia therapy is capable of impacting these outcomes. This study was carried out with the objective of describing the clinical characteristics and the diagnostic aids made to newborns with HIE undergoing total body hypothermia therapy and the use of criteria for admission to therapy in a sample of two institutions in the city of Medellin. METHODS: A descriptive retrospective study was conducted, including all patients with HIE admitted to hypothermia therapy during 2017 and 2018. RESULTS: The data of 256 patients (males 182; 71.1 %) were obtained. There were flaws in the registry and subjectivity in the application of the entry criteria to the hypothermia protocol in both institutions. In 197 (77 %) patients there was no report of sentinel event and the prolonged labour was considered by the clinicians as a significant finding when defining the entrance to the therapy. There were also admitted patients who did not meet the criterion of APGAR ≤ 5 at 10 minutes (n = 136). The results suggest the need to improve adherence to the protocol for admission to therapy; but at the same time, it points out the importance of the clinician's concept when dealing with each patient individually.

Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies / Infecciones fúngicas como consecuencia de tratamientos con anticuerpos monoclonales y otras terapias inmunomoduladoras

Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in a wide range of important physiologic processes and has a pathologic role in some diseases. TNF antagonists (infliximab, adalimumab, etanercept) are effective in treating inflammatory conditions. Antilymphocyte biological agents (rituximab, alemtuzumab), integrin antagonists (natalizumab, etrolizumab and vedolizumab), interleukin (IL)-17A blockers (secukinumab, ixekizumab) and IL-2 antagonists (daclizumab, basiliximab) are widely used after transplantation and for gastroenterological, rheumatological, dermatological, neurological and hematological disorders. Given the putative role of these host defense elements against bacterial, viral and fungal agents, the risk of infection during a treatment with these antagonists is a concern. Fungal infections, both opportunistic and endemic, have been associated with these biological therapies, but the causative relationship is unclear, especially among patients with poor control of their underlying disease or who are undergoing steroid therapy. Potential recipients of these drugs should be screened for latent endemic fungal infections. Cotrimoxazole prophylaxis could be useful for preventing Pneumocystis jirovecii infection in patients over 65 years of age who are taking TNF antagonists, antilymphocyte biological agents or who have lymphopenia and are undergoing concomitant steroid therapy. As with other immunosuppressant drugs, TNF antagonists and antilymphocyte antibodies should be discontinued for patients with active infectious disease

El factor de necrosis tumoral (TNF) es una citocina proinflamatoria involucrada en una amplia gama de procesos fisiológicos importantes y desarrolla un papel en la patogenia de algunas enfermedades. Los antagonistas del TNF (infliximab, adalimumab, etanercept) son efectivos en el tratamiento de afecciones inflamatorias. Los agentes biológicos antilinfocitarios (rituximab, alemtuzumab), los antagonistas de la integrina (natalizumab, etrolizumab y vedolizumab), de la interleucina 17A (secukinumab, ixekizumab) o los antagonistas de la IL-2 (daclizumab, basiliximab) se usan ampliamente después del trasplante y en trastornos gastroenterológicos, reumatológicos, dermatológicos, neurológicos y hematológicos. Dado el papel relevante de estos elementos de defensa del huésped contra agentes bacterianos, virales y fúngicos, el riesgo de infección durante el tratamiento con estos antagonistas genera preocupación. Las infecciones por hongos, tanto oportunistas como endémicos, se han asociado con estas terapias biológicas, pero la relación causal no está clara, especialmente entre los pacientes con un control deficiente de su enfermedad subyacente o que están recibiendo terapia con esteroides. Los pacientes en tratamiento con estos medicamentos deben ser examinados para detectar infecciones micóticas endémicas latentes. La profilaxis con cotrimoxazol podría ser útil para prevenir la infección por Pneumocystis jirovecii en pacientes mayores de 65 años que estén tomando antagonistas de TNF, agentes biológicos antilinfocitarios, o tengan linfopenia y estén en tratamiento concomitante con esteroides. Al igual que con otros fármacos inmunosupresores, deben suspenderse los antagonistas de TNF y los anticuerpos antilinfocitarios en pacientes con enfermedad infecciosa activa hasta su control

Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies.

Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in a wide range of important physiologic processes and has a pathologic role in some diseases. TNF antagonists (infliximab, adalimumab, etanercept) are effective in treating inflammatory conditions. Antilymphocyte biological agents (rituximab, alemtuzumab), integrin antagonists (natalizumab, etrolizumab and vedolizumab), interleukin (IL)-17A blockers (secukinumab, ixekizumab) and IL-2 antagonists (daclizumab, basiliximab) are widely used after transplantation and for gastroenterological, rheumatological, dermatological, neurological and hematological disorders. Given the putative role of these host defense elements against bacterial, viral and fungal agents, the risk of infection during a treatment with these antagonists is a concern. Fungal infections, both opportunistic and endemic, have been associated with these biological therapies, but the causative relationship is unclear, especially among patients with poor control of their underlying disease or who are undergoing steroid therapy. Potential recipients of these drugs should be screened for latent endemic fungal infections. Cotrimoxazole prophylaxis could be useful for preventing Pneumocystis jirovecii infection in patients over 65 years of age who are taking TNF antagonists, antilymphocyte biological agents or who have lymphopenia and are undergoing concomitant steroid therapy. As with other immunosuppressant drugs, TNF antagonists and antilymphocyte antibodies should be discontinued for patients with active infectious disease.

Características clínicas y electroencefalográficas de los pacientes con Síndrome de Lennox-Gastaut en el programa de epilepsia de la U. Antioquia. Medellín 2007 - 2012. / Clinical and electroencephalographic characteristics of patients with Lennox-Gastaut Syndrome within the epilepsy program attended at Antioquia University. Medellin 2007 - 2012

Objetivo: describir las características clínicas y electroencefalográficas en una muestra de pacientes con síndrome de Lennox-Gastaut diagnosticados en el programa de epilepsia de la Universidad de Antioquia en Medellín entre 2007 y 2012. Materiales y métodos: se trata de un estudio observacional, descriptivo y retrospectivo. La población de estudio estuvo conformada por todos los registros de pacientes con diagnóstico de síndrome de Lennox-Gastaut incluidos en la base de datos del programa de epilepsia de la Universidad de Antioquia y que fueron evaluados por videomonitoreo electroencefalográfico. Las variables clínicas y electroencefalográficas fueron examinadas. Para el análisis se utilizó el programa estadístico SPSS. Resultados: se revisaron 18 videotelemetrías. El promedio de edad fue 19,89 años, con igualdad de género en un 50%. La mitad de los pacientes presentaba antecedentes perinatales de riesgo. La edad promedio de la primera crisis fue de 4,67 años y el número promedio de crisis por semana fue de 31,17. Las crisis más frecuentes fueron las ausencias atípicas en 17 pacientes (94,4%). El medicamento más utilizado fue el ácido valproico. En todos los pacientes se encontró retardo mental y los hallazgos electroencefalográficos característicos del síndrome, tanto en vigilia como en sueño. En el sueño superficial se observó la mayoría de anormalidades. Conclusiones: el síndrome de Lennox-Gastaut es una de las encefalopatías epilépticas más severas de inicio en la niñez, conlleva grandes costos sociales y económicos y tiene un pobre pronóstico debido a sus condiciones mórbidas asociadas.

Objetive: To describe the clinical and electroencephalographic features in a sample of patients diagnosed with Lennox-Gastaut syndrome. The patients were part of the epilepsy program at the University of Antioquia in Medellin between 2007 and 2012. Materials and methods: This was completed with an observational, descriptive and retrospective method. The data used was taken from the records of all patients diagnosed with Lennox-Gastaut syndrome included in the epilepsy program at the University of Antioquia and who were evaluated by EEG video monitoring. Clinical and electroencephalographic variables were analyzed. For the analysis we used SPSS. Resualts: We reviewed 18 video EEG. The average age of the patients was 19,89 years, with the gender being equally being balanced. Half of the patients had a prenatal risk. The average age of the first seizure was at 4,67 years and the average number of attacks per week was 31,17. The most frequent were atypical absence seizures in 17 patients (94,4%). The most commonly used drug was valproic acid. All patients experienced mental retardation and characteristic electroencephalographic findings of the syndrome, during both times of wakefulness and sleep. Most abnormalities were observed during superficial sleep. Conclusions: The Lennox-Gastaut syndrome is one of the most severe epileptic encephalopathies with onset during childhood and with large social and economic costs and poor prognosis due to its associated morbid conditions.

Structural, dynamical, and electronic transport properties of modified DNA duplexes containing size-expanded nucleobases.

Among the distinct strategies proposed to expand the genetic alphabet, size-expanded nucleobases are promising for the development of modified DNA duplexes with improved biotechnological properties. In particular, duplexes built up by replacing canonical bases with the corresponding benzo-fused counterparts could be valuable as molecular nanowires. In this context, this study reports the results of classical molecular dynamics simulations carried out to examine the structural and dynamical features of size-expanded DNAs, including both hybrid duplexes containing mixed pairs of natural and benzo-fused bases (xDNA) and pure size-expanded (xxDNA) duplexes. Furthermore, the electronic structure of both natural and size-expanded duplexes is examined by means of density functional computations. The results confirm that the structural and flexibility properties of the canonical DNA are globally little affected by the presence of benzo-fused bases. The most relevant differences are found in the enhanced size of the grooves, and the reduction in the twist. However, the analysis also reveals subtle structural effects related to the nature and sequence of benzo-fused bases in the duplex. On the other hand, electronic structure calculations performed for xxDNAs confirm the reduction in the HOMO-LUMO gap predicted from the analysis of the natural bases and their size-expanded counterparts, which suggests that pure size-expanded DNAs can be good conductors. A more complex situation is found for xDNAs, where fluctuations in the electrostatic interaction between base pairs exerts a decisive influence on the modulation of the energy gap.